KTTA Pasithea Therapeutics Corp

$KTTA .48c break and hold will be massive good news, like the volume .. need more good luck

$KTTA looks interesting on here. FDA just cleared PAS-004 to move into a Phase 2 trial for NF1-associated cutaneous neurofibromas. That's a meaningful step for the company, especially with no FDA-approved systemic treatments specifically for this condition. Over 5.4M shares traded today, roughly 13x relative volume. They've also got a KOL event tomorrow at 11 AM ET, followed by initial NF1 patient data presentations November 12–14. Still needs to prove itself above resistance but ww

$KTTA Trust me or not, but I’ve been sharing some killer free plays ever since I came back full time. Hope some of you guys have been catching some of these plays and locking in profits. Called this around .38 and now it's pushing toward .53. 🔥

$KTTA They haven’t offered any support here even once—just a mention. It seems they’ve forgotten about the boss.

$KTTA is moving on FDA approval following a Globe Newswire release. Pasithea Therapeutics received FDA clearance for IND application to advance PAS-004, an oral MEK inhibitor, into Phase 2 trials for NF1-associated cutaneous neurofibromas. RTPR pushed this release out to users at 7:00:00 AM ET

THE GOAT OF STOCKTWITS🐐. FOLLOW he called CLRO before it went on a 300% RECENTLY. DUDE JUST DOESN’T MISS🙌 Hope bulls banked here today $KTTA $IFBD $REED

$KTTA new hod, slow climb into power hour maybe we hit .60 ? it was up there a few months back.

$KTTA I watched how the other guys trade. I’m a Korean trader myself, so I’ll give it a shot in the Korean market starting tomorrow... haha.

$KTTA here we go, now lets see.. if this runs up, peel off some profits as always great job so far bulls!

$KTTA made a nice move from our .38–.40 entry zone, pushing all the way toward .48 following this morning's FDA news. Seeing some profit-taking off the highs now, which isn't surprising after that move. They still have the KOL event tomorrow and NF1 clinical data presentations Nov 12–14. Let's see if the momentum sticks around

$KTTA Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)

$KTTA 🏥 Pasithea Therapeutics announced positive Phase 1 data for PAS-004 in advanced cancer, showing prolonged stable disease in four heavily pretreated patients for over 300 days, including two on once-daily treatment for over 500 days, with no Grade 3 treatment-related adverse events.

$KTTA Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026